MX2018006559A - Nuevos polipeptidos de fusion anti-angiogenicos. - Google Patents
Nuevos polipeptidos de fusion anti-angiogenicos.Info
- Publication number
- MX2018006559A MX2018006559A MX2018006559A MX2018006559A MX2018006559A MX 2018006559 A MX2018006559 A MX 2018006559A MX 2018006559 A MX2018006559 A MX 2018006559A MX 2018006559 A MX2018006559 A MX 2018006559A MX 2018006559 A MX2018006559 A MX 2018006559A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion polypeptides
- fusion
- ang
- vegf
- compositions
- Prior art date
Links
- 230000004927 fusion Effects 0.000 title abstract 10
- 229920001184 polypeptide Polymers 0.000 title abstract 10
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 10
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 10
- 230000001772 anti-angiogenic effect Effects 0.000 title 1
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 abstract 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 abstract 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 2
- 102000047202 human LCN2 Human genes 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15197019 | 2015-11-30 | ||
| PCT/AU2016/051168 WO2017091850A1 (en) | 2015-11-30 | 2016-11-30 | Novel anti-angiogenic fusion polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018006559A true MX2018006559A (es) | 2019-06-12 |
Family
ID=54754521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018006559A MX2018006559A (es) | 2015-11-30 | 2016-11-30 | Nuevos polipeptidos de fusion anti-angiogenicos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10703810B2 (OSRAM) |
| EP (1) | EP3383921A4 (OSRAM) |
| JP (1) | JP2019505565A (OSRAM) |
| KR (1) | KR20180083943A (OSRAM) |
| CN (1) | CN108699162A (OSRAM) |
| AU (1) | AU2016363668A1 (OSRAM) |
| BR (1) | BR112018010887A2 (OSRAM) |
| CA (1) | CA3004918A1 (OSRAM) |
| EA (1) | EA035586B1 (OSRAM) |
| MX (1) | MX2018006559A (OSRAM) |
| SG (2) | SG10201911499TA (OSRAM) |
| WO (1) | WO2017091850A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015104406A2 (en) * | 2014-01-13 | 2015-07-16 | Pieris Ag | Multi-specific polypeptide useful for localized tumor immunomodulation |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| CN109829882B (zh) * | 2018-12-18 | 2020-10-27 | 广州比格威医疗科技有限公司 | 一种糖尿病视网膜病变分期预测方法 |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| WO2022199603A1 (en) * | 2021-03-25 | 2022-09-29 | Nanjing GenScript Biotech Co., Ltd. | Antibody fusion proteins and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0257956B2 (en) | 1986-08-19 | 2000-11-22 | Genentech, Inc. | Use of polypeptide growth factors and cytokines for the manufacture of a device and of a dispersion |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| AU696387B2 (en) | 1994-05-18 | 1998-09-10 | Inhale Therapeutic Systems, Inc. | Methods and compositions for the dry powder formulation of interferons |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| WO1996023879A1 (en) | 1995-01-30 | 1996-08-08 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (en) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Method for preparing dispersions of chromogenic components |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| CN1170543C (zh) | 1998-06-08 | 2004-10-13 | 弗·哈夫曼-拉罗切有限公司 | PEG-IFN-α和三唑核苷在治疗慢性丙型肝炎中的用途 |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| AU2003264100A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| WO2006056464A2 (en) | 2004-11-26 | 2006-06-01 | Pieris Ag | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) |
| US20090305963A1 (en) * | 2005-01-19 | 2009-12-10 | Sukhatme Vikas P | Lipocalin 2 for the Treatment, Prevention, and Management of Cancer Metastasis, Angiogenesis, and Fibrosis |
| WO2007038619A2 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| JP2011501673A (ja) | 2007-10-19 | 2011-01-13 | アボット・ラボラトリーズ | グリコシル化された哺乳動物ｎｇａｌ及びその使用 |
| KR20110013409A (ko) * | 2008-05-23 | 2011-02-09 | 삼성전자주식회사 | 항체-펩티드 융합 상승체 |
| JP5711118B2 (ja) | 2008-06-24 | 2015-04-30 | テクニッシュ ウニヴェルジテート ミュンヘン | 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| JP2012521768A (ja) * | 2009-03-27 | 2012-09-20 | ジモジェネティクス・インコーポレイテッド | 抗体−受容体の組み合わせを含む多特異的結合性タンパク質を用いるための組成物および方法 |
| EP3660510A3 (en) | 2009-12-07 | 2020-07-08 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
| AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| EP3299386A1 (en) | 2010-08-16 | 2018-03-28 | Pieris Pharmaceuticals GmbH | Binding proteins for hepcidin |
| US9260492B2 (en) | 2010-11-15 | 2016-02-16 | Pieris Ag | Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3) |
| MX361337B (es) * | 2012-07-13 | 2018-12-04 | Roche Glycart Ag | Anticuerpos biespecificos anti-factor de crecimiento endotelial vascular humano (vegf) / anti-angiopoyetina-2 humana (ang-2) y su uso en el tratamiento de enfermedades vasculares oculares. |
| EP3441400B1 (en) | 2012-11-19 | 2022-07-20 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| KR20210094669A (ko) * | 2013-04-29 | 2021-07-29 | 에프. 호프만-라 로슈 아게 | 인간 fcrn-결합 변형된 항체 및 사용 방법 |
| WO2015104406A2 (en) * | 2014-01-13 | 2015-07-16 | Pieris Ag | Multi-specific polypeptide useful for localized tumor immunomodulation |
| US10774119B2 (en) * | 2014-05-22 | 2020-09-15 | Pieris Pharmaceuticals Gmbh | Specific-binding polypeptides and uses thereof |
| AU2016212087B2 (en) * | 2015-01-28 | 2019-11-07 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for angiogenesis |
| AR103477A1 (es) * | 2015-01-28 | 2017-05-10 | Lilly Co Eli | Compuestos de vegfa / ang2 |
| CR20170425A (es) | 2015-02-18 | 2017-11-22 | Sanofi Sa | Nuevas proteínas específicas para pioverdina y pioquelina |
| CN114573680A (zh) | 2015-05-04 | 2022-06-03 | 皮里斯制药有限公司 | Cd137特异性的蛋白 |
| BR112017020961A2 (pt) | 2015-05-18 | 2018-07-10 | Pieris Pharmaceuticals Gmbh | muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação |
-
2016
- 2016-11-30 EA EA201891141A patent/EA035586B1/ru not_active IP Right Cessation
- 2016-11-30 SG SG10201911499TA patent/SG10201911499TA/en unknown
- 2016-11-30 SG SG11201803732PA patent/SG11201803732PA/en unknown
- 2016-11-30 EP EP16869402.4A patent/EP3383921A4/en not_active Withdrawn
- 2016-11-30 AU AU2016363668A patent/AU2016363668A1/en not_active Abandoned
- 2016-11-30 US US15/777,340 patent/US10703810B2/en not_active Expired - Fee Related
- 2016-11-30 KR KR1020187018593A patent/KR20180083943A/ko not_active Withdrawn
- 2016-11-30 CA CA3004918A patent/CA3004918A1/en not_active Abandoned
- 2016-11-30 MX MX2018006559A patent/MX2018006559A/es unknown
- 2016-11-30 JP JP2018546726A patent/JP2019505565A/ja active Pending
- 2016-11-30 WO PCT/AU2016/051168 patent/WO2017091850A1/en not_active Ceased
- 2016-11-30 CN CN201680080597.2A patent/CN108699162A/zh active Pending
- 2016-11-30 BR BR112018010887A patent/BR112018010887A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP3383921A1 (en) | 2018-10-10 |
| WO2017091850A1 (en) | 2017-06-08 |
| BR112018010887A2 (pt) | 2018-11-21 |
| EP3383921A4 (en) | 2019-04-17 |
| AU2016363668A1 (en) | 2018-05-24 |
| CN108699162A (zh) | 2018-10-23 |
| SG11201803732PA (en) | 2018-06-28 |
| EA035586B1 (ru) | 2020-07-10 |
| KR20180083943A (ko) | 2018-07-23 |
| US20180334499A1 (en) | 2018-11-22 |
| JP2019505565A (ja) | 2019-02-28 |
| CA3004918A1 (en) | 2017-06-08 |
| EA201891141A1 (ru) | 2018-10-31 |
| SG10201911499TA (en) | 2020-01-30 |
| US10703810B2 (en) | 2020-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018006559A (es) | Nuevos polipeptidos de fusion anti-angiogenicos. | |
| MX384075B (es) | Nuevas proteínas específicas para la angiogénesis. | |
| ZA202501799B (en) | Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications | |
| PH12020551317A1 (en) | Anti-cd73 antibodies and methods of use thereof | |
| PH12020551907A1 (en) | Antagonizing cd73 antibody | |
| MX2018001567A (es) | Novedosos polipeptidos de fusion especificos para lag-3 y pd-1. | |
| PH12020551019A1 (en) | IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
| WO2017191274A3 (en) | Rna encoding a therapeutic protein | |
| PH12017501473A1 (en) | Novel proteins specific for pyoverdine and pyochelin | |
| CR20230026A (es) | Proteínas de fusión gdf15 y usos de estas (divisional 2018-0532) | |
| PH12019500709A1 (en) | Anti-lag-3 antibodies and methods of use thereof | |
| PH12017501583A1 (en) | Novel proteins specific for cd137 | |
| MX2017014083A (es) | Polipeptido de fusion anti-cancer. | |
| MX2021007085A (es) | Variante de interleucina-2 humana o derivado de la misma. | |
| MX2019014695A (es) | Proteinas de fusion de interleucina-2 y usos de las mismas. | |
| HK1246316A1 (zh) | 细胞因子融合蛋白 | |
| HK1258509A1 (zh) | Gitr激动剂 | |
| WO2015177175A3 (en) | Novel specific-binding polypeptides and uses thereof | |
| MX2019014504A (es) | Inmunoglobulinas de union a agrecano. | |
| EA201991409A3 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
| NZ732978A (en) | Il-17a-binding polypeptides | |
| MX2021012047A (es) | Polipeptidos de fusion de serpina y metodos para utilizar los mismos. | |
| PH12022550460A1 (en) | Anti-cd96 antibodies and methods of use thereof | |
| PH12020550483A1 (en) | Anti-apoc3 antibodies and methods of use thereof | |
| MX373912B (es) | Terapias antibioticas peptidicas derivadas del bufalo de agua |